share_log

UroGen Pharma Analyst Ratings

URoGen製薬アナリストの評価

Benzinga ·  2023/08/01 06:20
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/01/2023 149.31% HC Wainwright & Co. $23 → $54 Maintains Buy
07/31/2023 -16.9% Goldman Sachs $11 → $18 Maintains Neutral
06/21/2023 6.19% HC Wainwright & Co. → $23 Reiterates Buy → Buy
05/15/2023 1.57% Oppenheimer → $22 Reiterates Outperform → Outperform
05/15/2023 6.19% HC Wainwright & Co. → $23 Reiterates Buy → Buy
05/02/2023 6.19% HC Wainwright & Co. → $23 Reiterates → Buy
04/10/2023 6.19% HC Wainwright & Co. → $23 Reiterates → Buy
02/16/2023 6.19% HC Wainwright & Co. → $23 Reiterates → Buy
02/08/2023 -53.83% Jefferies $35 → $10 Downgrades Buy → Hold
12/12/2022 6.19% HC Wainwright & Co. $26 → $23 Maintains Buy
04/27/2022 -7.66% Berenberg → $20 Initiates Coverage On → Buy
03/22/2022 -49.22% Goldman Sachs $10 → $11 Maintains Neutral
01/18/2022 56.97% HC Wainwright & Co. $50 → $34 Maintains Buy
04/27/2021 130.84% HC Wainwright & Co. $57 → $50 Maintains Buy
04/17/2020 116.99% Oppenheimer $45 → $47 Maintains Outperform
04/16/2020 163.16% HC Wainwright & Co. $53 → $57 Reiterates → Buy
04/13/2020 144.69% HC Wainwright & Co. $75 → $53 Maintains Buy
04/06/2020 107.76% Oppenheimer $47 → $45 Maintains Outperform
01/13/2020 140.07% Oppenheimer $62 → $52 Maintains Outperform
11/13/2019 80.06% JP Morgan $40 → $39 Maintains Neutral
05/30/2019 89.29% JP Morgan → $41 Initiates Coverage On → Neutral
05/29/2019 130.84% Goldman Sachs → $50 Initiates Coverage On → Neutral
01/29/2019 278.58% HC Wainwright & Co. → $82 Initiates Coverage On → Buy
11/08/2018 255.49% Jefferies → $77 Assumes → Buy
09/14/2018 223.18% Stifel → $70 Initiates Coverage On → Buy

What is the target price for UroGen Pharma (URGN)?

The latest price target for UroGen Pharma (NASDAQ: URGN) was reported by HC Wainwright & Co. on August 1, 2023. The analyst firm set a price target for $54.00 expecting URGN to rise to within 12 months (a possible 149.31% upside). 10 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for UroGen Pharma (URGN)?

The latest analyst rating for UroGen Pharma (NASDAQ: URGN) was provided by HC Wainwright & Co., and UroGen Pharma maintained their buy rating.

When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

Is the Analyst Rating UroGen Pharma (URGN) correct?

While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $23.00 to $54.00. The current price UroGen Pharma (URGN) is trading at is $21.66, which is out of the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする